Drug Trial Radar · NCT01825512
Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
Last checked: Nov 20, 2026Latest source record: May 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
435
Actual
Start
Mar 17, 2014
Primary completion
Sep 21, 2017
Study completion Sep 21, 2017
Sponsor
- Lead sponsor
- Consorzio per Valutazioni Biologiche e FarmacologicheAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Commission
- First posted
- Apr 5, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 month, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate efficacy and safety of a 12-months treatment with deferiprone (DFP) at dose of 75-100 mg/kg/day versus deferasirox (DFX) at dose of 20-40 mg/kg/day in paediatric patients (1 month \< 18 years old) affected by hereditary haemoglobinopathies and requiring frequent transfusions and chelation.
Conditions
- Chronic Iron Overload
Interventions
DeferiproneDrug
Deferiprone 80 mg/mL oral solution
DeferasiroxDrug
Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Successfully Chelated PatientsTime frame: at baseline and after 12 months
Locations
22 sites in 7 countries. Site status is shown where the registry gives one.
Hospital 'Ihsan Çabej'
Lushnje, Albania
Qendra Spitalore Universitare "Nene Tereza" Tirane
Tirana, Albania
Department of Medical and Public health Services of the Ministry of Health
Nicosia, Cyprus
Alexandria University Hospital - Faculty of Medicine
Alexandria, Egypt
Cairo University Faculty of Medicine
Cairo, Egypt
Zagazig University Hospitals
Zagazig, Egypt
National And Kapodistrian University of Athens
Athens, Greece
Università di Bari - Facoltà di Medicina
Bari, Italy
ASL Cagliari Ospedale Regionale per le Microcitemie
Cagliari, Italy
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi
Catania, Italy
Presidio Ospedaliero "Annunziata", Centro di Studi della Microcitemia
Cosenza, Italy
A.O.Universitaria Meyer
Florence, Italy
Clinica Pediatrica Policlinico di Modena
Modena, Italy
Azienda Ospedaliera di Rilievo Nazionale "Antonio Cardarelli"
Naples, Italy
Azienda Ospedaliera di Padova
Padova, Italy
Ospedali Riuniti Villa Sofia - Cervello
Palermo, Italy
U.O.C. Ematologia - Emoglobinopatie, Ospedale G. Di Cristina
Palermo, Italy
Clinica Pediatrica Università - ASL 1 D.H per Talassemia
Sassari, Italy
Centro di Thalassemia, Ospedale Civile di Lentini
Lentini, SR, Italy
Centre National de Greffe de Moelle Osseuse Tunis
Tunis, Tunisia
Barts Health NHS Trust
London, United Kingdom
Queen's Hospital
Romford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.